Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NK:BOB1-TCR + IL-15
- Development stage
- Preclinical
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
**NK:BOB1-TCR + IL-15** is an investigational, engineered cell therapy consisting of natural killer (NK) cells that have been genetically modified to express a T cell receptor (TCR) specific for the BOB1 antigen (a B cell-specific transcription factor, also known as POU2AF1), combined with autonomous expression of interleukin-15 (IL-15). This combination endows the NK cells with dual mechanisms of cytotoxicity—TCR-mediated, directed against BOB1/HLA-B*07:02 positive tumor cells (such as multiple myeloma), and innate NK cell-mediated cytotoxicity, while IL-15 production supports the proliferation, survival, and persistence of the engineered cells without external cytokine support. Preclinical studies show enhanced anti-tumor activity and improved persistence in vivo, but also note the risk of potential toxicity due to cell accumulation in organs. The approach is being investigated for the treatment of B cell malignancies, especially multiple myeloma[1][4].
- Other names
- NK:BOB1-TCR/IL-15
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)BOB1/HLA-B*07:02 (B-cell-specific transcription coactivator OBF-1 (BOB1) peptide presented by Human Leukocyte Antigen B*07:02 (HLA-B*07:02))
Beyond the preview
Go deeper on NK:BOB1-TCR + IL-15.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NK:BOB1-TCR + IL-15.